Kala Pharmaceuticals to Present at Bank of America Merrill Lynch 2019 Health Care Conference

WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company
focused on the development and commercialization of therapeutics using
its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery
Technology, today announced that it will present at the Bank of America
Merrill Lynch 2019 Health Care Conference in Las Vegas, NV. Mark Iwicki,
Chairman, President and Chief Executive Officer of Kala Pharmaceuticals,
is scheduled to provide a corporate overview on Tuesday, May 14, 2019 at
8:15 a.m. PT (11:15 a.m. ET).

To access a live webcast and subsequent archived recording of the
presentation, please visit the “Investors & Media” section on the Kala
website at http://kalarx.com

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the development and
commercialization of therapeutics using its proprietary AMPPLIFY™
mucus-penetrating particle (MPP) Drug Delivery Technology, with an
initial focus on the treatment of eye diseases. Kala has applied the
AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol
etabonate (LE), designed for ocular applications, resulting in recently
approved INVELTYS™ for the treatment of inflammation and pain following
ocular surgery and its lead product candidate, KPI-121 0.25%, for the
temporary relief of the signs and symptoms of dry eye disease, for which
a New Drug Application (NDA) was accepted for review with the United
States Food and Drug Administration (FDA) and a target action date under
the Prescription Drug User Fee Act (PDUFA) has been set for August 15,
2019.

Contacts

Investors:
Michael Schaffzin, 212-362-1200
michael.schaffzin@sternir.com
or
Media:
Kari
Watson, 781-235-3060
kwatson@macbiocom.com